18F-FDG PET/CT in Differentiated Thyroid Carcinoma

Larg

2020

JPM

In thyroid neoplastic pathology, the BRAF V600E mutation is shown to be involved in the oncogenesis of papillary thyroid cancer and its subtypes. The purpose of this study is to evaluate the correlation between the mutation of the BRAF V600E oncogene and the pathological standardized uptake values (SUV) at the F18-fluorodeoxyglucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) evaluation, for a group of 20 patients with radically treated (total thyroidectomy and radioiodine therapy) papillary thyroid cancer, with subclinical persistent disease, at 6 months after the initial treatment. We analyzed the correlations between the values of SUV and the presence of the BRAF mutation as well with other prognostic factors such as stage, age, specific tumor markers (thyroglobulin and anti-thyroglobulin), extrathyroid extension, the presence of metastatic lymph nodes or distant metastasis. The value of SUV in the case of BRAF+ (positive) patients was higher than in the negative ones, but without statistical significance, thus, the values of the SUV cannot be a predictable factor for the presence of the genetic mutation. There was a statistically significant correlation in BRAF+ subgroup between the SUV values and the positive resection limit following surgery, showing a higher SUV value in the PET/CT evaluation. No correlation was observed between the aforementioned prognostic factors involved in papillary thyroid cancer and the BRAF V600E mutation.

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers

Larg

2020

JPM

“…[ 10 ] The most common indications for 18F-FDG PET/CT scan in thyroid carcinoma are the elevated thyroglobulin levels, but negative I-131 whole body scan and neck USG. [ 11 ]…”

Section: Discussionmentioning

confidence: 99%

18F-fluorodeoxyglucose positron emission tomography/computed tomography finding in a rare case of follicular carcinoma of thyroid with rhabdoid morphology

et al. 2021

Rhabdoid tumor commonly occurs in the kidney and has an aggressive clinical course with high mortality. Extrarenal rhabdoid tumours can involve a number of organs, but poorly differentiated follicular carcinoma with rhabdoid phenotype is an extremely rare clinical entity. The 18F-FDG PET feature of this thyroid malignancy is not available in the literature to the best of our knowledge. But, this feature has significant clinical relevance in management of such patients. We present such a case.

“…According to the recommendation provided by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for ovarian cancer Version 1.2020 [17], PET/CT is indicated during the initial evaluation, monitoring/follow-up (chest/abdominal/pelvic CT, MRI, PET/CT, or PET as clinically indicated), and for recurrent disease in any stages after primary treatment in the following situations: rising CA-25 with no previous chemotherapy, clinical relapse with no previous chemotherapy, clinical relapse after previous chemotherapy, and serially rising CA-125 values after previously administered chemotherapy. On the other hand, this imaging method is routinely recommended in the evaluation of malignant thyroid pathology [35][36][37].…”

Section: Discussionmentioning

confidence: 99%

Left Supraclavicular Lymph Node Metastasis from Ovarian Cancer Associated with Papillary Thyroid Microcarcinoma, a Confusing Pathology-Essential Role of Functional Imaging

et al. 2020

The revolution of imaging in medicine leads to new standards of care, mostly in specialties like oncology, neurology, or endocrinology. We present a review of the literature and a case report of a 62-year-old patient initially treated for a benign gynecologic pathology and followed-up for 7 years clinically, with serologic and with multiple imaging techniques. There is an actual growing use of highly sensitive functional imaging methods, like fluoro-deoxy-glucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) in the evaluation of oncologic pathologies, staging, follow-up, and therapy response monitoring. This is the first case report described in the literature presenting the association of thyroid papillary microcarcinoma (MPTC) and supraclavicular metastasis of ovarian cancer. The study aims to underline the necessity of a complex and careful evaluation of each oncologic patient, due to the unexpected clinical presentation and rare association of diseases, sometimes leading to confusing management.